Tenaya Therapeutics, Inc.

Tenaya Therapeutics is a U.S.-based clinical-stage biotechnology company focused on discovering and developing therapies for heart disease. Its pipeline includes gene therapies and small molecules built around human genetics, with programs aimed at both rare inherited cardiomyopathies and more prevalent cardiovascular conditions.

6.84

— Tenaya Therapeutics, Inc.
	%
Clinical-stage gene therapies	0% AAV-based therapies designed to address inherited heart disease at the genetic level.
Small-molecule cardiovascular therapy	0% Oral or systemic drug candidates targeting heart failure and related indications.
Preclinical discovery programs	0% Earlier-stage programs using gene addition, editing, silencing and regeneration approaches.
Manufacturing and process development capabilities	0% Internal and partnered capabilities for AAV process development, QC and clinical supply.

Tenaya does not sell commercial products today; its near-term customers are clinical trial participants, investigators,...

Clinical trial participantsprimary
Patients enrolled in MyPEAK-1, RIDGE-1 and other studies to evaluate safety and activity.
Clinical investigators and trial sitesprimary
Hospitals, academic centers and investigators that administer and monitor studies.
Specialty cardiology practicessecondary
Potential future prescribers for approved therapies in inherited cardiomyopathy and HFpEF.
Third-party payorssecondary
Commercial and government payors that would determine reimbursement and access.
Strategic pharmaceutical partnerssecondary
Potential collaborators for late-stage development and commercialization of TN-301 and other assets.

Tenaya is headquartered in South San Francisco, California and incorporated in Delaware, with operations centered in...

•Headquartered in South San Francisco, California
•Incorporated in Delaware
•Core research, development and manufacturing activities are U.S.-based
•Future approvals could expand into Europe and other foreign markets
•No product revenue has been generated to date

Tenaya’s strategy is to build disease-modifying therapies for heart disease using human genetics, AAV gene therapy and...

Generate clinical data for lead programsshort-term

Clinical readouts are needed to validate the platform and support regulatory advancement.

Preserve and extend cash runwayshort-term

Development-stage biotech requires capital to fund trials, manufacturing and regulatory work.

Build commercial and manufacturing readinessmedium-term

Gene therapies require reliable AAV supply, quality control and scale-up capability.

Pursue strategic partnering for larger indicationsmedium-term

Broader diseases such as HFpEF may require global resources for late-stage development and launch.

Tenaya faces the typical risks of a clinical-stage biotech company: uncertain trial outcomes, regulatory approval risk,...

high

Clinical development failure

Lead programs may not demonstrate sufficient safety or efficacy to advance.

Scope: TN-201, TN-401, TN-301
Materiality: High

high

Regulatory approval risk

Gene and small-molecule candidates require lengthy, uncertain FDA and foreign review.

Scope: All pipeline programs
Materiality: High

high

Capital dependence

The company has not generated product revenue and relies on external financing.

Scope: Corporate funding and trial execution
Materiality: High

medium

Manufacturing and supply chain execution

AAV therapies require consistent process control, quality and supply availability.

Scope: Clinical and future commercial supply
Materiality: High

medium

Intellectual property competition

Competing therapies and patent challenges could reduce the value of the pipeline.

Scope: HCM, ARVC and HFpEF programs
Materiality: High

Research and development expense accruals

Can create quarter-to-quarter volatility in operating loss

Stock-based compensation

Affects reported operating expenses and loss per share

Fair value of marketable securities

Can influence liquidity presentation and non-operating results

Clinical trial and manufacturing commitments

Important for assessing runway and spending cadence

Tenaya Therapeutics, Inc.

Clinical development failure

Regulatory approval risk

Capital dependence

Manufacturing and supply chain execution

Intellectual property competition

TENAX THERAPEUTICS, INC.

Aldeyra Therapeutics, Inc.

Coya Therapeutics, Inc.

TherapeuticsMD, Inc.

Sedana Medical

ANAPTYSBIO, INC